JoanneBWeidhaasMDPHD, MSM

PubMed

• 517 citations
  A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non–Small Cell Lung Cancer Risk
  Lena J. Chin, Elena Ratner, Shuguang Leng, Rihong Zhai, Sunitha Nallur
  Cancer Research. 2008-10-15
• 84 citations
  A Let-7 MicroRNA SNP in the KRAS 3′UTR Is Prognostic in Early-Stage Colorectal Cancer
  Kim M. Smits, Trupti Paranjape, Sunitha Nallur, Kim A.D. Wouters, Matty P. Weijenberg
  Clinical Cancer Research. 2011-10-12
• 74 citations
  MicroRNA signatures differentiate uterine cancer tumor subtypes.
  Elena Ratner, David Tuck, Christine E. Richter, Sunitha Nallur, Rajeshvari Patel
  Gynecologic Oncology. 2010-09-01

Journal Articles

• A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab M...  
  Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S, Clin Cancer Res, 9/1/2014
• A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma  
  Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 7/1/2014
• Radiation therapy oncology group gynecologic oncology working group: comprehensive results  
  Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr, Int J Gynecol Cancer, 6/1/2014
• Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society f...  
  Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, ..., Int J Radiat Oncol Biol Phys, 1/1/2014
• Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis  
  Kunos CA, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB and Gaffney DK, Int J Gynecol Cancer, 5/1/2013
• SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers  
  Preskill, C. and Weidhaas, JB, Crit Rev Oncog, 1/1/2013
• The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer  
  Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP, PLoS One, 5/1/2012
• miRNAs in the spotlight: Making ‘silent’ mutations speak up  
  Salzman, DW, Weidhaas JB, Nature Medicine, 8/1/2011
• A variant in a microRNA complementary site in the 3’UTR of the KIT oncogene increases risk of acral melanoma  
  Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidha..., Oncogene, 3/1/2011
• An increase in the prevalence of the variant allele rs61764370 T>G in the 3’UTR of KRAS among Dutch BRCA1, but not BRCA2 and non-BRCA1/BRCA2 breast cancer families  
  Antoinette Hollestelle, Cory Pelletier, Maartje Hooning, Ellen Crepin, Mieke Schutte, Maxime Look, J. Margriet Collee, Anja Nieuwlaat, Lambert C.J. Dorssers, Caroline ..., BCRT, 1/1/2011
• MicroRNAs as Potential Diagnostics and Therapeutics  
  Trupti Paranjape, Jae Choi, Joanne B. Weidhaas, MicroRNAs in Cancer, 1/1/2011
• MicroRNA signatures differentiate uterine cancer tumor subtypes  
  E Ratner, D Tuck, C Richter, S Nallur, R Patel, V schultz, P Hui, P Schwartz, T Rutherford and J Weidhaas, Gynecologic Oncology, 1/1/2010
• Using microRNAs to understand cancer biology  
  Weidhaas, J, Lancet Oncology, 1/1/2010
• MicroRNA binding site polymorphisms as biomakers of cancer risk  
  Pelletier C, Weidhaas JB, Expert. Rev. Mol. Diagn, 1/1/2010
• Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128  
  Weidhaas JB, S. Li, K. Winter, J. Ryu, A. Jhingran, B. Miller, A. P. Dicer, D. Gaffney, Clinical Cancer Research, 1/1/2009
• Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for the Optimization of Planning of Radiation Therapy  
  Kuo PH, Chen Z, and Weidhaas JB, Applied Radiology, 8/1/2008
• microRNA Modulation of the Cellular Stress Response  
  Imran A. Babar, Frank J. Slack, Weidhaas JB, Future Oncol, 1/1/2008
• MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy  
  Weidhaas JB, Imran Babar, Phong Trang, Sunitha M. Nallur, Sarah Roush, Michelle Boehm, Erin Gillespie and Frank J. Slack, Cancer Research, 1/1/2007
• A conserved Ras/Mitogen-Activated Protein Kinase Pathway Regulates DNA Damage-Induced Cell Death Postirradiation in Radelegans  
  Weidhaas JB, D.M. Eisenmann, J.M. Holub and S. Nallur, Cancer Research, 1/1/2006
• Relationship Between Gene Transcription and Retroviral DNA Integration  
  Weidhaas JB, E. Angelichio, S. Fenner and J.M. Coffin, J Virol, 1/1/1999
• Distribution of Targets for Avian Retrovirus DNA Integration In Vivo  
  S. Withers Ward, Y. Kitamura, Barnes JP, J.M. Coffin, Genes Dev, 1/1/1994
• Leukocyte Common Antigen-Related Receptor-Linked Tyrosine Phosphatase - Regulation of mRNA Expression  
  M. Longo, J.A. Martignetti, J.M. Le Beau, J.S. Zhang, Barnes JP, J. Brosius, J Biol Chem, 1/1/1993
• Hypothermia Protects Brain Function in Acute Carbon Monoxide Poisoning  
  B. Sutariya, D. Penney, Barnes JP, and C. Helfman, Vet Hum Toxicol, 1/1/1989
• Join now to see all

Lectures

• The KRAS-variant in Head and Neck Cancer as a Predictive Biomarker, results of RTOG 0522 
  6/1/2014
• MicroRNAs in cancer risk, biology and treatment 
  4/1/2014
• Yale Cancer Center Evening Oncology Series: Breast Cancer 
  Yale CME, New Haven, Connecticut - 1/17/2012
• The KRAS-variant in cancer 
  1/1/2012
• Being a Translational Researcher in Radiation Oncology 
  5/1/2011
• The potential of 3’UTR mutations in cancer 
  4/1/2011
• The KRAS-variant in HBOC 
  2/1/2011
• 3’UTR variants and cancer risk, a new paradigm 
  4/1/2010
• The KRAS-variant and MiRNA Biomarkers of Cancer Risk 
  2/1/2010
• MicroRNAs in Cancer Risk and Response 
  1/1/2010
• miRNA Binding Site Polymorphism and Ovarian Cancer Risk 
  11/1/2009
• Understanding miRNAs and cancer 
  9/1/2009
• The onco-SNP as a Biomarker of Ovarian Cancer Risk 
  5/1/2009
• A Single Nucleotide Polymorphism Disrupting MicroRNA Pathways and Predicting an Increased Risk for Ovarian Cancer 
  2/1/2009
• The microRNA let-7 and Lung Cancer 
  2/1/2008
• The Role of the EGFR-Pathway in Accelerated Repopulation after Radiation Therapy or Chemotherapy in C. elegans 
  2/1/2005
• A C. elegans In Vivo Model of Mitotic Cell Death and the Ras/MAPK Pathway 
  12/1/2003
• An In Vivo Tissue-Model of Post-Mitotic Cell Death and EGFR-Signaling in C. elegans 
  10/1/2003
• A C. elegans Model of Radiation Induced Post-Mitotic Cell Death 
  4/1/2003
• An In Vivo Tissue Model of Post-Mitotic Cell Death in C. elegans 
  1/1/2003
• Ras/MAPK-mediated Radiation Resistance in C. elegans 
  4/1/2002
• Transcriptional Activity Does Not Lead to Increased Retroviral Integration In Vivo 
  5/1/1997
• Join now to see all